Learning to live with the “new normal” … or avoid it if you can

Very, very, very slowly it appears that we are starting to see some serious interest in research into the psychosocial impact of prostate cancer and its treatment on men and their close family members and/or intimate partners. … READ MORE …

How broadly is your doctor smiling?

Dr. Craig Hildreth is a medical oncologist who writes a regular blog about issues related to the management of patients with cancer on the CancerNetwork web site. … READ MORE …

Tomatoes and plants and eating well to limit risk

New data just published (and associated with the ProtecT trial in the UK) has again suggested the value of tomatoes in the diet as a way to lower risk for prostate cancer — presumably because of the high levels of lycopene in tomatoes. … READ MORE …

Living with late stage prostate cancer

There is a valuable video interview that was put on line a couple of days ago featuring Dr. William Oh of the Mount Sinai Hospital and Medical School in New York and Jan Manarite of the Prostate Cancer Research Institute. … READ MORE …

Baseline data from the ProtecT trial … with outcomes still to come

Many readers of this blog will be interested to look through the data on the preliminary study design and diagnostic and baseline results of the randomized, phase III ProtecT trial that have just been reported in The Lancet Oncology. … READ MORE …

Of risk and reality — the role of prostate cancer testing in young, high-risk patients

None of the trials conducted to date have provided sound information as to the risk and benefits associated with PSA testing among younger men (aged, say, between 35 and 50 years of age) who have well-known risk factors for prostate cancer. … READ MORE …

New form of experimental immunotherapy for men with progressive mCRPC

A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination  with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,134 other followers